Dongyao Pharmaceutical-B (01875.HK) issued an announcement regarding the relevant connected transactions involving the issuance and issuance of subscribed shares to Shengde Pharmaceutical Factory and Weiwu Suzhou Fund. On July 29, 2022, all prerequisites under each subscription agreement were met and the subscription matters were fully completed. Accordingly, Shengde Pharmaceutical Factory has been allocated and issued 33.75 million subscribed shares; and Viwu Suzhou Fund has been allocated and issued approximately 116 million subscribed shares.
As of the close of July 29, 2022, Dongyao Pharmaceutical-B (01875.HK) closed at 3.11 yuan, up 0.0%, turnover rate of 0.0%, trading volume of 0,000 shares and trading volume of 0,000 yuan. Investment banks have little attention to the stock, and no investment bank has given it a rating within 90 days.
Dongyao Pharmaceutical-B has a market value of 1.913 billion yuan, ranking 42nd in the biologics II industry. The main indicators are shown in the table below:
and above are compiled by Securities Star based on public information and have nothing to do with the position of this site. Securities Star does not guarantee the accuracy, completeness, validity, timeliness, etc. of all or part of the content of this information (including but not limited to text, video, audio, data and charts). If there are any problems, please contact us. This article is a data compilation and does not constitute any investment advice to you. Investment is risky, so please make prudent decisions.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-